Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.
Aflibercept biosimilars have cleared several hurdles on their way to marketplace
Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly Diagnosed Geographic Atrophy: An Observational, Retrospective US-based Cohort Study at the annual Retina Society meeting being held this year in Lisbon, Portugal
According to the organization, the map and report provide public, professionals and decisionmakers with data on children’s vision issues at the county and state level.
The companies’ eye care line will feature refreshed design and improved packaging for Ocucyn Eyelid and Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago.
Prem Subramanian, MD, PhD, a professor of ophthalmology at the Sue Anschutz-Rodgers Eye Center, will use high-tech ocular equipment to monitor the four-member Polaris Dawn crew to investigate why eyes change in space.
Push to identify biomarkers for earlier diagnosis, new therapeutic targets.
Researchers from NYU Langone published a study reporting on the eye's functioning, without sight but offering hope for the future.
Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.
The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.
Identifying all genetic culprits may improve diagnostics and prognoses.
Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.
Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.
APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.
The contract research organization and technology solution is for the execution of ophthalmology clinical trials.
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025
In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.
BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.
The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.
Investigators at the Dean McGee Eye Institute reviewed the accuracy of the tools in measuring 5 vision assessment parameters, including distance visual acuity, near visual acuity, color vision testing, contrast sensitivity, and pupillary distance.
Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss Multiple Sclerosis and its association with reduced choroidal vascularity.
The non-diffractive, aspheric IOLs are the second generation of BVI’s ISOPURE family
The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).
A team of researchers at the Center for Regenerative Therapies Dresden of Dresden University of Technology is working to develop a method to replace or regenerate damaged photoreceptor cells in the human retina.
Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.
